All News

    Bevacizumab Biosimilars Reduce Costs While Maintaining Survival Outcomes in mCRC

    April 2nd 2025

    By Deana Ferreri, PhD

    Article

    Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness.

    Biosimilars Gastroenterology Roundup: March 2025

    April 1st 2025

    By Skylar Jeremias

    Article

    As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.

    Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year

    March 31st 2025

    By Skylar Jeremias

    Article

    Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming profitability of biosimilars despite financial hurdles.

    PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing

    March 30th 2025

    By Cameron Santoro

    Article

    Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.

    The Top 5 Biosimilar Articles for the Week of March 24

    March 28th 2025

    By Cameron Santoro

    Video

    Here are the top 5 biosimilar articles for the week of March 24, 2025.

    FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra

    March 27th 2025

    By Cameron Santoro

    Article

    The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.

    As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount

    March 27th 2025

    By Luke Halpern

    Article

    Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.

    Adalimumab Biosimilars Show Similar Outcomes in Psoriasis After Nonmedical Switch

    March 26th 2025

    By Skylar Jeremias

    Article

    Switching between adalimumab products does not affect drug effectiveness or treatment duration in patients who have psoriasis, according to a Danish study.

    Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS

    March 25th 2025

    By Cameron Santoro

    Article

    Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential as a cost-effective treatment option.

    BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio

    March 24th 2025

    By Sarfaraz K. Niazi, PhD

    Article

    Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.